A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus (HARMONY Outcomes)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms Harmony Outcomes
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 01 May 2017 Planned End Date changed from 14 May 2019 to 22 Mar 2018.
- 01 May 2017 Planned primary completion date changed from 1 May 2019 to 8 Feb 2018.